Key Quantitative Figures

  • Acquisition cost: ₹75 lakhs for 10% stake
  • Upakarma's authorized share capital: ₹2.00 crores
  • Upakarma's paid-up share capital: ₹1.80 crores
  • Upakarma turnover (FY26): ₹18.02 crores
  • Upakarma turnover (FY25): ₹13.06 crores
  • Upakarma turnover (FY24): ₹23.04 crores

Dates of Action

  • Share Purchase Agreement date: June 2, 2026
  • Acquisition completion date: June 2, 2026
  • Upakarma incorporation date: November 28, 2017
  • Upakarma became step-down subsidiary of Mankind Pharma: November 9, 2022
  • Disclosure date: June 2, 2026

Parties Involved

  • Acquiring entity: Mankind Lifesciences Private Limited (MLS) - wholly owned subsidiary of Mankind Pharma Limited
  • Target entity: Upakarma Ayurveda Private Limited
  • Seller: Kaushcorp Media LLP
  • Disclosing entity: Mankind Pharma Limited (Scrip Code: 543904, Symbol: MANKIND)

Transaction Details

  • MLS acquired remaining 10% stake in Upakarma from Kaushcorp Media LLP
  • Consideration method: Cash payment (₹75 lakhs payable in two tranches as per SPA)
  • Pre-acquisition holding: MLS held 90% stake in Upakarma
  • Post-acquisition holding: MLS holds 100% stake in Upakarma
  • Upakarma becomes wholly owned subsidiary of MLS and step-down wholly owned subsidiary of Mankind Pharma Limited

Business Details of Acquired Entity

  • Upakarma business: Trading/selling of ayurvedic, herbal and nutraceutical products
  • Industry: Ayurvedic, herbal and nutraceutical products
  • Geographic presence: India
  • Operational since: November 28, 2017

Transaction Classification

  • Classified as Related Party Transaction
  • Conducted at arm's length basis
  • Promoters or promoter group of the Company have no interest in this acquisition

Purpose and Impact

  • The acquisition will enable the Company to achieve better operational efficiencies through streamlined processes
  • The business is within the main line of business of the listed entity